Thrombin generation and the pharmacodynamics of parenteral anticoagulants
- 10 April 2026
- journal article
- review article
- Published by Elsevier in Pharmacological Reviews
- Vol. 78 (3) , 100135
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Bayer
- LEO Pharma Research Foundation
This publication has 227 references indexed in Scilit:
- Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With CancerJAMA, 2023
- Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between‐subject variationResearch and Practice in Thrombosis and Haemostasis, 2022
- Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated ThrombogramResearch and Practice in Thrombosis and Haemostasis, 2021
- Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular ThrombiJAMA Cardiology, 2020
- Comparison of antithrombin‐dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clotsResearch and Practice in Thrombosis and Haemostasis, 2018
- A review of commercially available thrombin generation assaysResearch and Practice in Thrombosis and Haemostasis, 2018
- Hemostatic Response in Paediatric Patients Undergoing Cardiopulmonary Bypass SurgeryPediatric Cardiology, 2011
- Identification of Patients at Low Risk for Recurrent Venous Thromboembolism by Measuring Thrombin GenerationJAMA, 2006
- The Use of Fluorogenic Substrates to Monitor Thrombin Generation for the Analysis of Plasma and Whole Blood CoagulationAnalytical Biochemistry, 2000
- Implications for function and therapy of a 2.9 å structure of binary-complexed antithrombinJournal of Molecular Biology, 1998